$-0.12
(Market cap
$2,131 Mln
Recently Viewed
Clear AllMarket cap
$2,131 Mln
Revenue (TTM)
$2,198 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
86.3
Debt to Equity
0.9
Book Value
$10.9
EPS
$-6.8
Face value
--
Shares outstanding
104,989,772
CFO
$-2,762.99 Mln
EBITDA
$-3,340.74 Mln
Net Profit
$-3,963.14 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
| -5.7 | 14.6 | -3.9 | -65.9 | -45.9 | -22.1 | 3.1 |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
| -82.3 | 25.9 | -25.6 | 43.9 | -47.2 | 32.1 | 18.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sarepta Therapeutics Inc. (DE) (SRPT)
|
20.3 | 2,131.3 | 2,198.2 | -713.4 | -30.2 | -53.5 | -- | 1.9 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 229.3 | 14,164.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare... diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Read more
President, CEO & Director
Mr. Douglas S. Ingram Esq.
President, CEO & Director
Mr. Douglas S. Ingram Esq.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sarepta Therapeutics Inc (DE) (SRPT) is $20.30 (NASDAQ) as of 24-Apr-2026 16:20 EDT. Sarepta Therapeutics Inc (DE) (SRPT) has given a return of -45.87% in the last 3 years.
Since, TTM earnings of Sarepta Therapeutics Inc (DE) (SRPT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-3.17
|
1.98
|
|
2024
|
55.82
|
8.60
|
|
2023
|
-16.55
|
10.32
|
|
2022
|
-16.21
|
29.62
|
|
2021
|
-17.42
|
7.86
|
The 52-week high and low of Sarepta Therapeutics Inc (DE) (SRPT) are Rs 64.80 and Rs 10.42 as of 27-Apr-2026.
Sarepta Therapeutics Inc (DE) (SRPT) has a market capitalisation of $ 2,131 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sarepta Therapeutics Inc (DE) (SRPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.